CHATSWORTH, Calif. - CHAD Therapeutics plans to launch its first product for the treatment of sleep disordered breathing sometime this summer, the company stated in a February release. "We are now developing our marketing strategy for these proprietary devices," President Earl Yager stated. For the nine months that ended Dec. 31, 2006, the manufacturer's revenue declined to $14.8 million compared to $17.2 million last year.
Comments